Research across Metabolic Dysfunction-Associated Steatohepatitis
Related studies from across the Metabolic Dysfunction-Associated Steatohepatitis family.
Efficacy of GLP-1 Receptor Agonists in Managing MASLD and MASH Clinical Outcomes
GLP-1 Drugs Linked to Less Liver Fat and Weight Loss
GLP-1 receptor agonists demonstrate significant reductions in liver fat, body weight, and transaminases in patients with MASLD or MASH.
A pooled analysis of 795 adults links GLP-1 drugs to less liver fat, lower liver enzymes, and modest weight loss in fatty liver disease.
mpMRI markers of liver disease are associated with lower health-related quality of life in MASH
Liver imaging markers linked to lower quality of life
This multinational real-world randomized controlled trial of 802 patients with suspected MASLD/MASH found that patients with MASH reported l…
New research shows that specific liver imaging markers are linked to lower quality of life and higher anxiety in patients with liver disease…
cGAS-STING pathway serves as a central axis for innate immune activation in MASLD and HCC
New research identifies a key immune pathway in fatty liver disease
This systematic review explores the role of the cGAS-STING pathway in metabolic dysfunction-associated steatotic liver disease and hepatocel…
A specific immune pathway called cGAS-STING may play a major role in how fatty liver disease progresses and leads to serious complications.
Higher histologic liver fibrosis stages correlate with increased risk of cirrhosis and hepatic decompensation
Liver Fibrosis Stages Linked to Higher Risk of Liver Failure
This meta-analysis of 32 studies evaluates the association between histologic liver fibrosis stages and clinical outcomes in patients with M…
Higher stages of liver fibrosis are linked to a significantly increased risk of liver failure and death in patients with fatty liver disease…
Resmetirom Improves MASH Resolution and Fibrosis in F2-F3 Patients
Trial shows resmetirom improves liver health in MASH patients
In a post hoc analysis of 917 MASH patients with F2-F3 fibrosis, resmetirom achieved significantly higher MASH resolution and fibrosis impro…
A Phase 3 trial shows that resmetirom may help resolve MASH and improve liver scarring in adults with specific stages of liver disease.
Placebo Arms Show 13.09 Cirrhosis Events per 100 Person-Years in Fibrotic MASH
Advanced Liver Scarring Risk Increases With Higher MASH Stages
This meta-analysis pooled placebo arms from randomized trials to estimate cirrhosis incidence in fibrotic MASH (F2-F3). Across 586 patients …
Patients with more advanced liver scarring from MASH face a significantly higher risk of developing cirrhosis over time.
GLP-1 Receptor Agonists for MASH: Protocol Aims to Synthesize Histological and Metabolic Outcomes
New plan to study GLP-1 drugs for fatty liver disease
This is a protocol for a systematic review and meta-analysis evaluating GLP-1 receptor agonists versus placebo or standard care in adults wi…
A new research plan aims to see if GLP-1 medications can improve liver health and reduce scarring in adults with MASH.
Phase 2 Trial Evaluating Zalfermin and Semaglutide Combinations for Metabolic Dysfunction Associated Steatohepatitis
Trial Shows Semaglutide May Impact Liver Fibrosis in MASLD
A 52-week trial assessed whether zalfermin combined with semaglutide improves liver fibrosis in patients with advanced steatohepatitis.
A new trial suggests semaglutide may improve liver fibrosis in patients with MASLD, while other combinations did not show significant result…
rs2896019 G allele associated with 51% increased risk of MASLD susceptibility
Genetic variant linked to increased risk of fatty liver disease
This meta-analysis of 15028 adults identified the rs2896019 polymorphism (G allele) as a significant risk factor for MASLD. The study found …
A specific genetic marker may significantly increase the risk of developing and progressing to severe fatty liver disease.
AI, machine learning, and deep learning models facilitate multimodal diagnosis and prognosis in MASLD
Artificial intelligence helps identify and predict fatty liver disease
This scoping review synthesizes 73 studies regarding the role of AI, machine learning, and deep learning in diagnosing and predicting outcom…
New technology is helping doctors identify fatty liver disease and predict its progress by analyzing complex data and medical images.
MicroRNAs influence lipid metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis progression
Small molecules called microRNAs may help track and treat liver disease
This systematic review examines the role of microRNAs (miRNAs) in the pathophysiology of nonalcoholic fatty liver disease. The authors synth…
New research highlights how tiny molecules called microRNAs influence liver inflammation and scarring, offering hope for better diagnosis an…
Semaglutide improves MASH resolution (OR 3.48) and liver fat reduction in MASLD patients
Semaglutide helps resolve liver inflammation in patients with MASH
This meta-analysis of 1908 patients with MASLD and MASH found that semaglutide significantly improved MASH resolution (OR 3.48) and reduced …
New data shows semaglutide can reduce liver fat and inflammation for people with fatty liver disease, though results on scarring vary.